Another recent meta-analysis study reported on the relationship between TPO-R agonists (eltrombopag, lusutrombopag, and avatrombopag) and the risk of portal vein thrombosis as well as arterial and venous thrombo-embolic events in patients with chronic liver disease and thrombocytopenia [76]. The gene discussed is MPL; the disease is Portal vein thrombosis.